BMY vs MRK
Bristol-Myers Squibb · Merck
| BMY Bristol-Myers Squibb Healthcare | MRK Merck Healthcare | |
|---|---|---|
| Market | ||
| Price | $62.48 +1.78% | $149.52 +2.18% |
| Market cap | $127.6B | $368.9B |
| P/E (TTM) | 13.8 | 116.3 |
| Dividend yield | 4.58% | 2.87% |
| 52-week range | $43.20 – $68.64 | $82.01 – $156.92 |
| Our research | ||
| Our view | LONG open | LONG open |
| Articles | 1 | 1 |
| Latest article | Bristol-Myers Squibb: The Forensic Case That The Patent Cliff Math Has Already Been Solved May 27, 2026 | Merck (MRK): Revenue Up 5%, But $550M Of Purchase Timing Was About Two-Thirds Of The Incr… Nov 1, 2026 |
| Latest earnings | ||
| Reported | Oct 29, 2026 | Oct 29, 2026 |
| Revenue | $13.1 billion +7% YoY | — |
| EPS | $1.05 | $2.04 |
| Guidance | Guidance raised | Guidance issued |
| Revenue growth, last 4 reports | +7% | — |
| Topics | ||
| Main topics | ||
| Company page · Earnings releases | Company page · Earnings releases | |
Note. Earnings figures are extracted automatically from each company's own release; prices are delayed up to 15 minutes. This comparison is information, not investment advice.